RSV vaccine prevents hospitalization in older adults

One dose of the respiratory syncytial virus vaccine prevented hospitalization from the disease in adults 60 and older during two RSV seasons, according to a study published in JAMA.

Among nearly 7,000 adults with RSV, the estimated vaccine effectiveness against hospitalization during two seasons was 58%. The effectiveness was 69% when vaccination occurred in the same season before illness onset and 48% when vaccination occurred in the prior season.

Ongoing monitoring is needed to determine the optimal RSV revaccination interval, according to the study.

Read more: JAMA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.